Question 1

Myelodysplastic syndromes sometimes share similar peripheral and bone marrow cellularity with all of the following except:

Accepted Answer

A)  Vitamin B12 deficiency 
B)  Aplastic anemia 
C)  Acute leukemia 
D)  Folate deficiency 
A)  Vitamin B12 deficiency 
B)  Aplastic anemia 
C)  Acute leukemia 
D)  Folate deficiency B

Question 2

All of the following are useful for predicting prognosis for patients with the myelodysplastic syndromes except:

Accepted Answer

A)  Degree of anemia 
B)  Cytogenetic findings 
C)  Number of cytopenias 
D)  Percent blast cells in the bone marrow 
A)  Degree of anemia 
B)  Cytogenetic findings 
C)  Number of cytopenias 
D)  Percent blast cells in the bone marrow A

Question 3

Which of following is an expected finding in myelodysplastic syndromes?

Accepted Answer

A)  Ringed sideroblasts in the bone marrow and siderocytes in the blood 
B)  Thrombocytosis and leukocytosis 
C)  Increased number of morphologically normal red cells 
D)  Dysmyelopoiesis but normal red cell precursors in the bone marrow 
A)  Ringed sideroblasts in the bone marrow and siderocytes in the blood 
B)  Thrombocytosis and leukocytosis 
C)  Increased number of morphologically normal red cells 
D)  Dysmyelopoiesis but normal red cell precursors in the bone marrow A

Question 4

Which of the following is true regarding the clinical course of the myelodysplastic syndromes?

Accepted Answer

A)  The course is variable based on cell counts and type of myleodysplastic syndrome. 
B)  Most patients survive an average of 10 years with minimal symptoms. 
C)  It has an aggressive course with most patients succumbing to infection in less than 1 year. 
D)  All cases convert to acute leukemia. 
A)  The course is variable based on cell counts and type of myleodysplastic syndrome. 
B)  Most patients survive an average of 10 years with minimal symptoms. 
C)  It has an aggressive course with most patients succumbing to infection in less than 1 year. 
D)  All cases convert to acute leukemia.

Question 5

Therapy-related myelodysplastic syndrome follows what type of treatment?

Accepted Answer

A)  Certain antibiotic agents for severe infection 
B)  Human growth factors such as CSF-GM 
C)  Corticosteroid agents for immune disorders 
D)  Chemotherapy and radiation for cancer 
A)  Certain antibiotic agents for severe infection 
B)  Human growth factors such as CSF-GM 
C)  Corticosteroid agents for immune disorders 
D)  Chemotherapy and radiation for cancer

Question 6

Which of the following is a common feature of the myelodysplastic syndromes?

Accepted Answer

A)  Peripheral blasts between 5% and 20% 
B)  Progressive cytopenias and dyspoiesis in one or more cell lines 
C)  Macrocytic red cells and leukocytosis 
D)  Low mean cell volume (MCV) and thrombocytopenia 
A)  Peripheral blasts between 5% and 20% 
B)  Progressive cytopenias and dyspoiesis in one or more cell lines 
C)  Macrocytic red cells and leukocytosis 
D)  Low mean cell volume (MCV) and thrombocytopenia

Question 7

Which of the following would be an unexpected finding in myleodysplastic syndrome with a deletion of 5q?

Accepted Answer

A)  Refractory anemia 
B)  Thrombocytosis 
C)  Less than 1% blasts in peripheral blood 
D)  Auer rods 
A)  Refractory anemia 
B)  Thrombocytosis 
C)  Less than 1% blasts in peripheral blood 
D)  Auer rods

Question 8

Cell dysfunction in the myelodysplastic syndromes may be present in:

Accepted Answer

A)  Red cells 
B)  Granulocytes 
C)  Platelets 
D)  All of the above 
A)  Red cells 
B)  Granulocytes 
C)  Platelets 
D)  All of the above

Question 9

What is the cause of myelodysplastic syndromes?

Accepted Answer

A)  Decreased apoptosis 
B)  Are inherited disorders 
C)  Proliferation of mutated myeloid cells 
D)  Epstein-Barr virus 
A)  Decreased apoptosis 
B)  Are inherited disorders 
C)  Proliferation of mutated myeloid cells 
D)  Epstein-Barr virus

Question 10

Which of the following is a typical finding in chronic myelomonocytic leukemia?

Accepted Answer

A)  Thrombocytosis 
B)  Leukopenia 
C)  10% to 15% Blasts in the peripheral blood 
D)  Absolute monocytosis 
A)  Thrombocytosis 
B)  Leukopenia 
C)  10% to 15% Blasts in the peripheral blood 
D)  Absolute monocytosis

Question 11

What test is most important in distinguishing one myelodysplastic syndrome from another?

Accepted Answer

A)  White blood count 
B)  Percentage of blasts in the bone marrow 
C)  Red cell morphology and MCV 
D)  Presence of ringed sideroblasts in the peripheral blood 
A)  White blood count 
B)  Percentage of blasts in the bone marrow 
C)  Red cell morphology and MCV 
D)  Presence of ringed sideroblasts in the peripheral blood

Question 12

What red cell morphology is expected in the myelodysplastic syndromes?

Accepted Answer

A)  Oval macrocytes 
B)  Dimorphic 
C)  Hypochromic, microcytic 
D)  Any of the above 
A)  Oval macrocytes 
B)  Dimorphic 
C)  Hypochromic, microcytic 
D)  Any of the above

Question 13

What is the major change the WHO made to the classifications of the myelodysplastic syndromes?

Accepted Answer

A)  Dropped the 5q syndrome from myleodysplastic syndromes 
B)  Reduced the percentage of blasts required for the diagnosis of acute myeloid leukemia from 30% to 20% 
C)  Recognized acute myeloid leukemia as one of the myleodysplastic syndromes 
D)  Created a new classification placing refractory anemia and the myeloproliferative disorders together 
A)  Dropped the 5q syndrome from myleodysplastic syndromes 
B)  Reduced the percentage of blasts required for the diagnosis of acute myeloid leukemia from 30% to 20% 
C)  Recognized acute myeloid leukemia as one of the myleodysplastic syndromes 
D)  Created a new classification placing refractory anemia and the myeloproliferative disorders together

Question 14

What treatment for the myelodysplastic syndromes has the best chance for cure in these patients?

Accepted Answer

A)  Corticosteroid agents 
B)  Chemotherapy 
C)  Bone marrow transplant 
D)  Vitamins and hormones 
A)  Corticosteroid agents 
B)  Chemotherapy 
C)  Bone marrow transplant 
D)  Vitamins and hormones

Question 15

Which of the following is typical in the peripheral blood in patients with myelodysplastic syndrome?

Accepted Answer

A)  Lymphocytosis 
B)  Plasma cells 
C)  Hypogranular or agranular neutrophils 
D)  Low levels of vitamin B12 or folate 
A)  Lymphocytosis 
B)  Plasma cells 
C)  Hypogranular or agranular neutrophils 
D)  Low levels of vitamin B12 or folate

Question 16

On what does the World Health Organization (WHO) base its classification for the myelodysplastic syndromes?

Accepted Answer

A)  Cell morphology 
B)  Molecular analysis 
C)  Cytogenetics 
D)  All of the above 
A)  Cell morphology 
B)  Molecular analysis 
C)  Cytogenetics 
D)  All of the above

Exam 35: Myelodysplastic Syndromes

Myelodysplastic syndromes sometimes share similar peripheral and bone marrow cellularity with all of the following except:

All of the following are useful for predicting prognosis for patients with the myelodysplastic syndromes except:

Which of following is an expected finding in myelodysplastic syndromes?

Which of the following is true regarding the clinical course of the myelodysplastic syndromes?

Therapy-related myelodysplastic syndrome follows what type of treatment?

Which of the following is a common feature of the myelodysplastic syndromes?

Which of the following would be an unexpected finding in myleodysplastic syndrome with a deletion of 5q?

Cell dysfunction in the myelodysplastic syndromes may be present in:

What is the cause of myelodysplastic syndromes?

Which of the following is a typical finding in chronic myelomonocytic leukemia?

What test is most important in distinguishing one myelodysplastic syndrome from another?

What red cell morphology is expected in the myelodysplastic syndromes?

What is the major change the WHO made to the classifications of the myelodysplastic syndromes?

What treatment for the myelodysplastic syndromes has the best chance for cure in these patients?

Which of the following is typical in the peripheral blood in patients with myelodysplastic syndrome?

On what does the World Health Organization (WHO) base its classification for the myelodysplastic syndromes?

An Overview of Clinical Laboratory Hematology

Safety in the Hematology Laboratory

Specimen Collection

Care and Use of the Microscope

Quality Assurance in Hematology and Hemostasis Testing

Cellular Structure and Function

Hematopoiesis

Erythrocyte Production and Destruction

Energy Metabolism and Membrane Physiology of the Erythrocyte

Hemoglobin Metabolism

Iron Metabolism

Leukocyte Development, Kinetics, and Functions

Platelet Production, Structure, and Function

Routine and Point-Of-Care Testing in Hematology: Manual and Semiautomated Methods

Examination of the Peripheral Blood Film and Correlation With the Complete Blood Count

Bone Marrow Examination

Body Fluids in the Hematology Laboratory

Anemias: Red Blood Cell Morphology and Approach to Diagnosis

Disorders of Iron and Heme Metabolism

Anemias Caused by Defects of Dna Metabolism

Bone Marrow Failure

Introduction to Increased Destruction of Erythrocytes

Intrinsic Defects Leading to Increased Erythrocyte Destruction

Extrinsic Defects Leading to Increased Erythrocytedestructionnonimmune Causes

Extrinsic Defects Leading to Increased Erythrocytedestructionimmune Causes

Hemoglobinopathies Structural Defects in Hemoglobin

Thalassemias

Nonmalignant Leukocyte Disorders

Introduction to Leukocyte Neoplasms

Cytochemistry

Cytogenetics

Molecular Diagnostics in the Clinical Laboratory

Flow Cytometric Analysis in Hematologic Disorders

Myeloproliferative Neoplasms

Acute Leukemias

Mature Lymphoid Neoplasms

Pediatric and Geriatric Hematology

Automated Cell-Counting Instrumentation

Normal Hemostasis and Coagulation

Hemorrhagic Coagulation Disorders

Thrombosis Risk Testing

Thrombocytopenia and Thrombocytosis

Qualitative Disorders of Platelets and Vasculature

Laboratory Evaluation of Hemostasis

Monitoring Antithrombotic Therapies

Coagulation Instrumentation

Filters